logo
Plus   Neg
Share
Email

AstraZeneca Says Farxiga Meets All Primary, Secondary Endpoints In Phase III DAPA-CKD Trial

AstraZeneca (AZN,AZN.L) announced that high-level results from Farxiga's Phase III DAPA-CKD trial showed a statistically significant and clinically meaningful effect on its primary endpoint of a composite of worsening of renal function or risk of death in adult patients with chronic kidney disease or CKD.

The trial also met all its secondary endpoints in CKD patients with and without type-2 diabetes or T2D, making Farxiga the first medicine to significantly reduce the risk of death from any cause in this patient population.

The safety and tolerability profile for Farxiga was consistent with the well-established safety profile of the medicine, the company said.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
General Electric Co. filed a lawsuit against Siemens Energy AG, accusing the German power distribution company of stealing trade secrets for gas turbines. Siemens Energy allegedly used the information to get at least nine contracts to supply gas turbines to public utilities, and also covered up improper business gains. Following a court ruling, the U.S. Food and Drug Administration postponed the effective date for tobacco manufacturing companies to display new health warnings on cigarette packets and in advertisements, by additional 90 days. The warnings with color images is to promote greater public understanding of the negative health consequences of smoking. JPMorgan Chase & Co (JPM) reported strong results in the fourth quarter of 2020, with net profit up 42% largely driven by credit reserve releases of $2.9 billion. The Group said it ended the year with a CET1 ratio of 13.1% and capital above $200 billion, providing with meaningful capacity to further...
Follow RTT